Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $7.6 million.

  • BioNexus Gene Lab's Liabilities and Shareholders Equity fell 3068.49% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 1731.66%. This contributed to the annual value of $10.4 million for FY2024, which is 847.34% down from last year.
  • As of Q3 2025, BioNexus Gene Lab's Liabilities and Shareholders Equity stood at $7.6 million, which was down 3068.49% from $9.4 million recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Liabilities and Shareholders Equity ranged from a high of $11.5 million in Q3 2023 and a low of $7.6 million during Q3 2025
  • Over the past 5 years, BioNexus Gene Lab's median Liabilities and Shareholders Equity value was $9.5 million (recorded in 2025), while the average stood at $9.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 86376.05% in 2021, then tumbled by 3068.49% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Liabilities and Shareholders Equity stood at $9.6 million in 2021, then decreased by 8.71% to $8.7 million in 2022, then skyrocketed by 30.43% to $11.4 million in 2023, then decreased by 8.47% to $10.4 million in 2024, then fell by 26.96% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $9.4 million for Q2 2025, and $9.5 million during Q1 2025.